HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[Study on the therapeutic effects of tetrandrine combined with N-acetylcysteine on experimental silicosis of rats].

AbstractOBJECTIVE:
To compare the effects of oral treatment with tetrandrine (TD) and N-acetylcys-teine (NAC) separately or jointly on silica-exposed rats.
METHODS:
40 sprague-Dawly (SD) rats were randomly divided into normal saline group, quartz group, TD treatment group (50 mg/kg), NAC treatment group (500 mg/kg) and combined treatment group (TD: 50 mg/kg + NAC: 500 mg/kg). Rats in normal saline group and other groups received intratracheal instillation of normal saline and quartz dust suspension respectively. Treatment groups were given TD, NAC separately or jointly via esophagus the next day after instillation, once a day and six times a week for 30 consecutive days. At the end of experiment, the pathological changes of lung tissues were evaluated by the methods of Foot, HE and Masson staining, the level of hydroxyproline (HYP), malondjalde-hyde (MDA), tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6) in lung tissues were measured by alkaline hydrolysis method, the barbituric acid method and enzyme-linked immunosorbent assay (ELISA) respectively.
RESULTS:
Compared with the quartz group, lymph nodes/body coefficients in all treatment groups and lung/body coefficient in combined treatment group were significantly decreased (P < 0.05). Pathology results showed that the normal saline group demonstrated no obvious evidence of lung damage. The quartz group lungs silicotic lesions focused on II~III level, the TD treatment group was mainly with I level, the NAC treatment group was mainly with I~II level, and the combined treatment group only showed little silicotic nodule, no obvious fibrosis. HYP content in TD treatment group and combined treatment group were significantly lower than that in the quartz group (P < 0.05), while it showed no obvious change in NAC treatment group. MDA content in lung tissues of each treatment group (TD treatment group, NAC treatment group and combined treatment group) were 18.80 ± 2.94, 20.13 ± 4.01 and 17.05 ± 3.52 nmol/ml respectively, which lower than in the quartz group (23.99 ± 3.26 nmol/ml). The level of IL-6 in lung tissues of the quartz group were 89.57 ± 8.78 pg/ml. After TD and NAC monotherapy, the IL-6 content decreased to 79.22 ± 9.65 pg/ml and 81.63 ± 5.72 pg/ml, and it decreased more significantly after combined medication (74.37 ± 3.17 pg/ml). The level of TNF-α in the quartz group were 59.05 ± 4.48 pg/ml. After TD and NAC monotherapy, the TNF-α content decreased to 50.48 ± 2.76 pg/ml and 54.28 ± 4.30 pg/ml, and it decreased more significantly after combined medication (49.10 ± 4.98 pg/ml).
CONCLUSION:
NAC and TD could reduce MDA, TNF-α and IL-6 levels in lung tissue, and alleviate SiO2-induced pulmonary fibrosis in rats. Combined treatment with TD and NAC was more effective than TD or NAC treatment separately.
AuthorsYun Xiao, Hailing Xia, Lijin Zhu, Xianfeng Li, Riping Chen, Xianhong Yin, Zhaoqiang Jiang, Lingfang Feng, Junqiang Chen, Min Yu, Jianlin Lou, Xing Zhang
JournalZhonghua lao dong wei sheng zhi ye bing za zhi = Zhonghua laodong weisheng zhiyebing zazhi = Chinese journal of industrial hygiene and occupational diseases (Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi) Vol. 33 Issue 7 Pg. 519-22 (Jul 2015) ISSN: 1001-9391 [Print] China
PMID26653649 (Publication Type: Journal Article)
Chemical References
  • Benzylisoquinolines
  • Dust
  • Interleukin-6
  • Tumor Necrosis Factor-alpha
  • Quartz
  • tetrandrine
  • Malondialdehyde
  • Silicon Dioxide
  • Hydroxyproline
  • Acetylcysteine
Topics
  • Acetylcysteine (pharmacology)
  • Animals
  • Benzylisoquinolines (pharmacology)
  • Disease Models, Animal
  • Dust
  • Hydroxyproline (metabolism)
  • Interleukin-6 (metabolism)
  • Lung (pathology)
  • Malondialdehyde (metabolism)
  • Pulmonary Fibrosis (chemically induced, drug therapy)
  • Quartz (toxicity)
  • Rats
  • Rats, Wistar
  • Silicon Dioxide (toxicity)
  • Silicosis (drug therapy)
  • Tumor Necrosis Factor-alpha (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: